| A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma (NCT01439568) | Eli Lilly and Company | 2011-09-01 |
| A Study of Teriparatide in Japanese Osteoporosis Patients (NCT01430104) | Eli Lilly and Company | 2011-08-01 |
| A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma (NCT01391130) | Eli Lilly and Company | 2011-08-01 |
| A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin (NCT01388335) | Eli Lilly and Company | 2011-08-01 |
| A Study of LY2216684 in Participants With Major Depression Disorder (NCT01370499) | Eli Lilly and Company | 2011-08-01 |
| A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes (NCT01408888) | Eli Lilly and Company | 2011-08-01 |
| A Study of LY2523355 in Participants With Breast Cancer (NCT01416389) | Eli Lilly and Company | 2011-08-01 |
| A Study in Adults With Type 1 Diabetes (NCT01421147) | Eli Lilly and Company | 2011-08-01 |
| A Study of Ejaculatory Dysfunction in Men With Low Testosterone Levels (NCT01419236) | Eli Lilly and Company | 2011-08-01 |
| A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors (NCT01316263) | Eli Lilly and Company | 2011-08-01 |
| Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) (NCT01394952) | Eli Lilly and Company | 2011-07-22 |
| A Study to Evaluate the Effect of Food on LY2216684 (NCT01389765) | Eli Lilly and Company | 2011-07-01 |
| A Study of LY2979165 in Healthy Subjects (NCT01383967) | Eli Lilly and Company | 2011-07-01 |
| A Bioavailability Study of LY2452473 and Tadalafil (NCT01401543) | Eli Lilly and Company | 2011-07-01 |
| A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement (NCT01369511) | Eli Lilly and Company | 2011-07-01 |
| A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects (NCT01389752) | Eli Lilly and Company | 2011-07-01 |
| An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes (NCT01400971) | Eli Lilly and Company | 2011-07-01 |
| A Relative Bioavailability and Food Effect Study of New Formulations (NCT01398475) | Eli Lilly and Company | 2011-07-01 |
| A Study of IMC-CS4 in Subjects With Advanced Solid Tumors (NCT01346358) | Eli Lilly and Company | 2011-06-15 |
| A Study of LY2216684 in Healthy Females (NCT01373931) | Eli Lilly and Company | 2011-06-01 |
| A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine (NCT01358968) | Eli Lilly and Company | 2011-06-01 |
| A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China (NCT01352507) | Eli Lilly and Company | 2011-06-01 |
| A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects (NCT01374178) | Eli Lilly and Company | 2011-06-01 |
| A Study in Pediatric Participants With Generalized Anxiety Disorder (NCT01226511) | Eli Lilly and Company | 2011-06-01 |
| An Open Label Study for Participants With Rheumatoid Arthritis (NCT01215942) | Eli Lilly and Company | 2011-06-01 |
| Single Dose Study in Healthy Participants to Investigate the Safety and Absorption of LY2584702 (NCT01372085) | Eli Lilly and Company | 2011-06-01 |
| Disposition of Carbon-14-Labeled LY2886721 ([^14C]-LY2886721) Following Oral Administration in Healthy Human Participants (NCT01367262) | Eli Lilly and Company | 2011-06-01 |
| A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer (NCT01373164) | Eli Lilly and Company | 2011-06-01 |
| A Study of LY2484595 in Japanese Subjects (NCT01375075) | Eli Lilly and Company | 2011-06-01 |
| A Study of LY2216684 in Healthy Participants (NCT01380691) | Eli Lilly and Company | 2011-06-01 |
| A Study of LY2881835 in Healthy People and People With Diabetes (NCT01358981) | Eli Lilly and Company | 2011-05-24 |
| A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors (NCT01341457) | Eli Lilly and Company | 2011-05-01 |
| A Study of LY2495655 in Healthy Subjects (NCT01341470) | Eli Lilly and Company | 2011-05-01 |
| A Study in Prevention of Re-emergence of Depression Symptoms (NCT01299272) | Eli Lilly and Company | 2011-05-01 |
| A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma (NCT01220271) | Eli Lilly and Company | 2011-04-01 |
| Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma (NCT01282463) | Eli Lilly and Company | 2011-04-01 |
| A Study in Participants With Diabetic Peripheral Neuropathic Pain in China (NCT01179672) | Eli Lilly and Company | 2011-04-01 |
| A Study of LY2409021 Formulations and the Effect of Food (NCT01354496) | Eli Lilly and Company | 2011-04-01 |
| Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies (NCT01175824) | Eli Lilly and Company | 2011-04-01 |
| A Study in Participants With End-Stage Renal Disease (NCT01200290) | Eli Lilly and Company | 2011-04-01 |
| A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer (NCT01246960) | Eli Lilly and Company | 2011-04-01 |
| A Study in Non-Small Cell Lung Cancer (NCT01232452) | Eli Lilly and Company | 2011-04-01 |
| A Study of LY2951742 in Healthy Volunteers (NCT01337596) | Eli Lilly and Company | 2011-04-01 |
| A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck (NCT01059643) | Eli Lilly and Company | 2011-04-01 |
| A Study of LY2157299 in Participants With Hepatocellular Carcinoma (NCT01246986) | Eli Lilly and Company | 2011-03-30 |
| A Study of LY2828360 in Patients With Osteoarthritic Knee Pain (NCT01319929) | Eli Lilly and Company | 2011-03-01 |
| Hospital Management of Hyperglycemia Study of Insulin Glargine Plus Insulin Lispro Versus Human Regular Insulin (NCT01136746) | Eli Lilly and Company | 2011-03-01 |
| A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment (NCT01187407) | Eli Lilly and Company | 2011-03-01 |
| A Study of the Effect of LY2189265 on Two Blood Pressure Drugs (NCT01324388) | Eli Lilly and Company | 2011-03-01 |
| A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor (NCT01185340) | Eli Lilly and Company | 2011-03-01 |
| A Study to Compare Two Forms of LY2608204 in Healthy People (NCT01313286) | Eli Lilly and Company | 2011-03-01 |
| A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome (NCT01237587) | Eli Lilly and Company | 2011-03-01 |
| A First Human Study of a Ferroportin Antibody (NCT01330953) | Eli Lilly and Company | 2011-03-01 |
| Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients (NCT01234402) | Eli Lilly and Company | 2011-03-01 |
| A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors (NCT01288989) | Eli Lilly and Company | 2011-03-01 |
| Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects (NCT01299285) | Eli Lilly and Company | 2011-02-01 |
| Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose (NCT01300260) | Eli Lilly and Company | 2011-02-01 |
| A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers. (NCT01301092) | Eli Lilly and Company | 2011-02-01 |
| A Study in Non Small Cell Lung Cancer (NCT01139775) | Eli Lilly and Company | 2011-02-01 |
| C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors (NCT01296568) | Eli Lilly and Company | 2011-02-01 |
| A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus (NCT01175811) | Eli Lilly and Company | 2011-02-01 |
| A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) (NCT01286818) | Eli Lilly and Company | 2011-02-01 |
| Disposition of 14C-LY2452473 Following Oral Administration in Healthy Human Subjects (NCT01275157) | Eli Lilly and Company | 2011-01-01 |
| A Study in Migraine Prevention (NCT01184508) | Eli Lilly and Company | 2011-01-01 |
| A Rheumatoid Arthritis Study in Participants (NCT01202760) | Eli Lilly and Company | 2011-01-01 |
| A Study in Participants With Rheumatoid Arthritis (NCT01202773) | Eli Lilly and Company | 2011-01-01 |
| A Study of LY2409021 in Patients With Type 2 Diabetes (NCT01241448) | Eli Lilly and Company | 2011-01-01 |
| A Study of LY2127399 in Participants With Systemic Lupus Erythematosus (NCT01205438) | Eli Lilly and Company | 2011-01-01 |
| A Study in Second Line Metastatic Colorectal Cancer (NCT01183780) | Eli Lilly and Company | 2010-12-02 |
| A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer (NCT01256567) | Eli Lilly and Company | 2010-12-01 |
| A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma (NCT01170663) | Eli Lilly and Company | 2010-12-01 |
| A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate (NCT01198002) | Eli Lilly and Company | 2010-12-01 |
| A Study of LY2127399 in Participants With Systemic Lupus Erythematosus (NCT01196091) | Eli Lilly and Company | 2010-12-01 |
| A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors (NCT01263223) | Eli Lilly and Company | 2010-12-01 |
| A Study of LY2216684 and Digoxin in Healthy Subjects (NCT01266590) | Eli Lilly and Company | 2010-12-01 |
| LY2189265 and Atorvastatin Interaction Study (NCT01250834) | Eli Lilly and Company | 2010-12-01 |
| Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes (NCT01215955) | Eli Lilly and Company | 2010-12-01 |
| A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy (NCT01168973) | Eli Lilly and Company | 2010-12-01 |
| A Safety Study of LY2886721 Multiple Doses in Healthy Subjects (NCT01227252) | Eli Lilly and Company | 2010-12-01 |
| A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel (NCT01263093) | Eli Lilly and Company | 2010-12-01 |
| A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol (NCT01263197) | Eli Lilly and Company | 2010-12-01 |
| A Study of Brain Receptor Occupancy in Healthy Subjects (NCT01232439) | Eli Lilly and Company | 2010-12-01 |
| A Study of LY2216684 and Theophylline in Healthy Subjects (NCT01263106) | Eli Lilly and Company | 2010-12-01 |
| A Study of the Effect of LY2216684 on Lorazepam (NCT01275144) | Eli Lilly and Company | 2010-12-01 |
| A Study of LY2216684 and Warfarin in Healthy Subjects (NCT01263119) | Eli Lilly and Company | 2010-12-01 |
| A Phase 1 Study of LY2874455 in Participants With Advanced Cancer (NCT01212107) | Eli Lilly and Company | 2010-12-01 |
| A Study of LY2439821 in Rheumatoid Arthritis (NCT01236118) | Eli Lilly and Company | 2010-12-01 |
| Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease (NCT01127633) | Eli Lilly and Company | 2010-12-01 |
| Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use (NCT01134107) | Eli Lilly and Company | 2010-11-01 |
| Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas (NCT01253525) | Eli Lilly and Company | 2010-11-01 |
| A Study in Participants With Acute Leukemia (NCT01214603) | Eli Lilly and Company | 2010-11-01 |
| A Study of LY2608204 in Patients With Type 2 Diabetes (NCT01247363) | Eli Lilly and Company | 2010-11-01 |
| A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer (NCT01165021) | Eli Lilly and Company | 2010-11-01 |
| A Study of LY3009104(Baricitinib) for Healthy Subjects (NCT01247350) | Eli Lilly and Company | 2010-11-01 |
| A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder (NCT01173601) | Eli Lilly and Company | 2010-11-01 |
| A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women (NCT01250145) | Eli Lilly and Company | 2010-11-01 |
| A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4) (NCT01191268) | Eli Lilly and Company | 2010-11-01 |
| A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment (NCT01257178) | Eli Lilly and Company | 2010-11-01 |
| A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline (NCT01250873) | Eli Lilly and Company | 2010-11-01 |
| A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment (NCT01253304) | Eli Lilly and Company | 2010-11-01 |